Fresenius Medical Care

Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The firm develops and manufactures health care products, which includes dialysis and non-dialysis products. It operates through the following segments: North America Segment, EMEA Segment, Asia-Pacific Segment and Latin America Segment. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades.

Fresenius Medical sees up to 2% US dialysis growth by year-end

Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up

Fresenius Medical Care AG (NYSE:FMS ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dominik Heger - Head, IR Helen Giza - CEO and Chair Martin Fischer - CFO Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg James Vane-Tempest - Jefferies Veronika Dubajova - Citi Graham Doyle - UBS Lisa Clive - Bernstein Robert Davies - Morgan Stanley Hugo Solvet - Exane BNP Paribas Oliver Metzger - ODDO BHF Falko Friedrichs - Deutsche Bank Dominik Heger Thank you, Alice. Good afternoon or good morning, depending on where you are.

Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript

Solid revenue1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income1 margin improved in both segments   Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin band Execution of transformation continues at pace, contributing additional FME25 savings of EUR 52 million Portfolio optimization program progresses in Care Delivery with signed or closed divestments in all our Latin American markets, and closed divestments in Turkiye and of Cura Day Hospitals Group in Australia FY 2024 outlook confirmed BAD HOMBURG, Germany , May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The first quarter of this year demonstrates that we are executing on our strategy as planned. Both segments expanded their respective margins compared to the prior year.

Fresenius Medical Care starts the year with strong earnings growth

Fresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher pricing and cost-cut savings, but the German company still maintained its profit outlook for 2024, sending its shares down in early trading.

Fresenius Medical beats earnings expectations, keeps outlook; shares sink

Baxter

Cardinal Health

Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.

Fresenius Medical (FMS) to Unveil Training on Augmented Reality

Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate target roadmap BAD HOMBURG, Germany , March 22, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system This learning experience reinforces initial training, a supplement to support new staff amidst the high fluctuation of specialists in intensive care nursing BAD HOMBURG, Germany , March 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards.

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role Jörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectors BAD HOMBURG, Germany , March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

Divestment of assets includes four separate country transactions to DaVita Inc. for USD 300 million Transactions further reduce the Company`s clinic footprint in Latin America, following the exit from Argentina at the end of 2023 Expected to close throughout 2024 Proceeds to be used to reduce debt BAD HOMBURG, Germany , March 5, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.

Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company?

Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up

Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript

Revenue growth of 5% in 2023 driven by favorable business development Operating income1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlement Successful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care Enablement Several key divestments announced as part of the ongoing Portfolio Optimization Program Strong cash flow performance and net financial leverage ratio reduced Dividend of €1.19 per share proposed For 2024 continued revenue growth and accelerated operating income growth projected BAD HOMBURG, Germany, Feb. 20, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "In 2023, we delivered on our commitments while we fundamentally transformed Fresenius Medical Care. Exceeding our upgraded financial outlook for the full year was the very successful finish to an extraordinary year.

Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.

Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System

Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S. The 510(k) clearance allows the start of clinical evaluations and user-studies in the U.S., with a planned broad commercial launch of the 5008X Hemodialysis System in 2025.

Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

BAD HOMBURG, Germany , Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives.

Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

Divestments in 2023 are important milestones of the Company's execution against its Portfolio Optimization which are part of the set strategic aspirations Delivers on commitment to improve leverage ratio by allocating expected EUR 0.5 billion proceeds from divestments to deleverage BAD HOMBURG, Germany , Jan. 8, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program. Refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of a disciplined and stringent approach to capital allocation.

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Fresenius Medical Care has seen a recovery in its share price after a dip in October 2023, presenting an attractive upside potential. The company's 3Q23 results showed continued organic growth, successful execution of its turnaround plan, and raised earnings outlook. While FMS still has average margins and profitability compared to its peers, it remains undervalued and offers a compelling investment opportunity.

Fresenius Medical Care: What Can We Expect For 2024E

Fresenius has hired UBS to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, citing financial sources.

Fresenius plans to sell rehabilitation care clinics - FAZ

Dialysis group Fresenius Medical Care said on Wednesday that data including medical records on 500,000 patients and former patients were stolen from a U.S. subsidiary's database.

Fresenius Medical Care says data on 500,000 people stolen in U.S.

Change of legal form simplifies the corporate governance structure as a German stock corporation (Aktiengesellschaft) The composition of the Management Board remains as before; the new Supervisory Board assumes office with immediate effect Business model and strategic plan remain strong and continue to translate into improved operating performance BAD HOMBURG, Germany , Nov. 30, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announces the successful completion of its change of legal form from a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a German stock corporation (Aktiengesellschaft, AG) as of November 30, 2023. With this important milestone, Fresenius Medical Care is opening a new chapter in the history of the Company with a simplified corporate governance structure that gives the Company more flexibility and autonomy.

Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.

News for Fresenius Medical Care Stock (FMS)